New hope for infants with severe epilepsy: fenfluramine trial launches
NCT ID NCT06118255
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing the safety and tolerability of fenfluramine (Fintepla) in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The drug is given as an oral solution twice daily alongside other seizure medications. Researchers will monitor heart health, growth, and seizure frequency to see if the drug is safe and effective in this young age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fenfluramine (oral solution)
What this could lead to
If successful, this could provide a treatment option for infants with Dravet syndrome to help reduce seizures.
What could go wrong
This is a small, single-arm study with no placebo group, so results may not be definitive. Fenfluramine has known risks for heart valve problems and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ep0213 103
Seattle, Washington, 98105, United States
-
Ep0213 105
Memphis, Tennessee, 38103-2800, United States
-
Ep0213 107
Dallas, Texas, 75207, United States
-
Ep0213 201
Roma, Italy
-
Ep0213 202
Florence, Italy
-
Ep0213 203
Genova, Italy
-
Ep0213 204
Roma, Italy
-
Ep0213 303
Bielefeld, Germany
-
Ep0213 401
London, United Kingdom
-
Ep0213 403
Glasgow, United Kingdom
-
Ep0213 501
Edegem, Belgium
-
Ep0213 502
Brussels, Belgium